DiscoverConversations in Drug DevelopmentDemystifying Regulatory Designations in Drug Development
Demystifying Regulatory Designations in Drug Development

Demystifying Regulatory Designations in Drug Development

Update: 2024-07-10
Share

Description

In this episode, Dr Katherine Bowen and Dr Julie Warner delve into the world of regulatory designations, providing clarity on what these designations offer, the products that qualify, and the pros and cons of each. They discuss the history of regulatory designations, starting with the Orphan Drug Act of 1983, and explore various designations such as Orphan Drug Designation (ODD), Fast Track Designation (FTD), Breakthrough Therapy Designation (BTD), and Regenerative Medicines Advanced Therapy Designation (RMAT).


Tune in to gain valuable insights from their experience and advice and learn how to navigate the regulatory landscape effectively.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Demystifying Regulatory Designations in Drug Development

Demystifying Regulatory Designations in Drug Development

Boyds